When something (like a LAIV , a live attenuated influenza vaccine) is described as “cold adapted,” it means the virus has been modified so it grows well at cooler temperatures but poorly at normal body temperature.

In practice, that means:

  • The vaccine virus replicates efficiently in the cooler upper airways (like the nose), where temperatures are lower than deep in the lungs.
  • It does not replicate well at the warmer temperatures found in the lower respiratory tract, which helps limit disease severity while still triggering an immune response.

So “cold adapted” is a safety-and-design feature: the virus is tuned to grow in cooler parts of the body and is weakened at normal core body temperature, allowing it to act as a vaccine without causing full-blown illness.